Table 1.
Patient characteristics
| Patient | Age | Diagnosis | Treatment 1 | Recurrence | Treatment 2 | Treatment 3 | Treatment 4 | MDX-CTLA-4 | Metastases |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 43 | Skin (MM) 1995 | Surgery | Parotid, lung 1998 | GVAX 7/98–2/99 | Chemo 2/99–9/99 | PS341 4/00–6/00 | 1/01 | CNS, lung, abdomen, skin |
| 2 | 56 | LN (MM) 1992 | Surgery, α-IFN | SC, perirenal, LN, 1998 | GVAX 6/98–11/99 | — | — | 1/01 | LN, bone, perirenal |
| 3 | 43 | LN (MM) 1997 | Surgery, α-IFN | LN, intestine 1998 | Surgery 12/98 | DC 4/00–9/00 | — | 11/00 | LN |
| 4 | 58 | Skin (MM) 1998 | Surgery, XRT | Skin, lung 2000 | DC 5/00–8/00 | XRT 8/00 | — | 1/01 | CNS, lung |
| 5 | 49 | Skin, LN (MM) 1998 | Surgery, α-IFN | SC 2000 | DC 11/00–2/00 | — | — | 4/01 | SC, lung, liver, LN |
| 6 | 52 | SC (MM) 1997 | Surgery, GM2 | LN, lung 2000 | gp100 12/00–3/01 | Chemo 4/01–6/01 | — | 7/01 | Lung, LN |
| 7 | 31 | Skin (MM) 1994 | Surgery | LN, lung, SC, CNS, 1996 | Surgery, chemo, 8/96 | GVAX 7/98–10/98 | Chemo, XRT 1/99–6/99, 2/01–10/01 | 9/02 | SC |
| 8 | 38 | Pelvis (OV) 1998 | Surgery, chemo | Lung, pelvis 7/99 | Chemo 8/99–12/99 | MUC-1 4/00–6/00 | Chemo, GVAX, CI-1033, 6/00, 4/01, 2/02 | 6/02 10/02 | Lung, pelvis, retroperitone |
| 9 | 65 | PER (OV) 1999 | Chemo | PER 2001 | Chemo 9/01–12/01 | Chemo 2/02–5/02 | GVAX 6/02–8/02 | 9/02 | PER |
MM, malignant melanoma; OV, ovarian carcinoma; SC, subcutaneous tissue; LN, lymph node; PER, peritoneum; GM2, ganglioside + QS-21; GVAX, irradiated, autologous tumor cells engineered to secrete GM-CSF; DC, dendritic cells engineered to express gp100 and MART-1; gp100, peptide plus IL-2; MUC-1, MUC-1 conjugated to KLH plus QS-21; XRT, radiation therapy; PS341, proteosome inhibitor; CI-1033, epidermal growth factor kinase inhibitor.